


AMENDMENTS


In the Claims:

1. (Currently Amended) A method of treating a ~~chemokine mediated disease state, or a disease state mediated by a receptor of the chemokine,~~ multiple sclerosis in a mammal in need of such treatment, which comprises administering to the mammal an effective amount of a compound ~~selected from the group consisting of compounds of formula (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), (XI), (XII), (XIII), (XIV) or (XV)~~ or a pharmaceutically acceptable salt thereof:


(I)




(II)




(III)




(IV)




(V)




(VI)




(VII)




(VIII)




(IX)




(X)




(XI)




(XII)




(XIII)



(XIV)



(XV)



wherein:

"a" is 0 or an integer from 1 to 8;

"b" is 0 or an integer from 1 to 7;

"c" is 0 or an integer from 1 to 6;

"d" is 0 or an integer from 1 to 10;

"e" is 0 or an integer from 1 to 10;

Ring A is aromatic or non-aromatic and may optionally be heterocyclic with one or more heteroatoms selected from the group consisting of oxygen, sulfur and nitrogen;

Ring B is aromatic or non-aromatic and may optionally be heterocyclic with one or more heteroatoms selected from the group consisting of oxygen, sulfur and nitrogen;

Ring C is aromatic or non-aromatic and may optionally be heterocyclic with one or more heteroatoms selected from the group consisting of oxygen, sulfur and nitrogen;

R₁, R₂ and R₃ at each occurrence may independently be selected from substituents having 25 or fewer atoms, wherein the substituent may be selected from the group consisting of: H;

substituted or unsubstituted alkyls; ~~substituted or unsubstituted C₁₋₁₀-alkyls; substituted or~~

~~unsubstituted C₁₋₆-alkyls; substituted or unsubstituted cycloalkyls; substituted or unsubstituted C₃₋₆~~
~~cycloalkyls; substituted or unsubstituted alkenyls; substituted or unsubstituted C₂₋₆-alkenyls;~~

substituted or unsubstituted alkynyls; ~~substituted or unsubstituted C₂₋₆-alkynyls;~~ substituted or

unsubstituted aryls; substituted or unsubstituted heterocycles; hydroxyls; aminos; nitros; thiols;

primary, secondary or tertiary amines; imines; amides; phosphonates; phosphines; carbonyls;

carboxyls; silyls; ethers; thioethers; sulfonyls; sulfonates; selenoethers; ketones; aldehydes;

esters; -CF₃; -CN; and combinations thereof;

R₄, R₅ and R₆ at each occurrence may independently be selected from substituents having 20 or fewer atoms, wherein the substituent may be selected from the group consisting of: H; substituted or unsubstituted alkyls; ~~substituted or unsubstituted C₁₋₁₀-alkyls; substituted or unsubstituted C₁₋₆-alkyls;~~ substituted or unsubstituted cycloalkyls; ~~substituted or unsubstituted C₃₋₆-cycloalkyls;~~ substituted or unsubstituted alkenyls; ~~substituted or unsubstituted C₂₋₆-alkenyls;~~ substituted or unsubstituted alkynyls; ~~substituted or unsubstituted C₂₋₆-alkynyls;~~ substituted or unsubstituted aryls; substituted or unsubstituted heterocycles; hydroxyls; aminos; nitros; thiols; primary, secondary or tertiary amines; imines; amides; phosphonates; phosphines; carbonyls; carboxyls; silyls; ethers; thioethers; sulfonyls; sulfonates; selenoethers; ketones; aldehydes; esters; -CF₃; -CN; and combinations thereof;

R₁, R₂, R₃, R₄, R₅ and R₆ may together define one or more exocyclic rings joining one or more of Rings A, B and C, and an exocyclic ring may be heterocyclic;


"chiral" denotes that a compound may be chiral; ~~and,~~

~~the chemokine receptor is selected from the group consisting of CCR-1, CCR-3, CCR-4 and CCR-5 and the chemokine is selected from the group consisting of RANTES and chemokines that bind to the chemokine receptor.~~

Claims 2 to 33 (Cancelled).

34. (Currently Amended) The method of claim 1, wherein the compound has the following formula:

(XIII)



Claims 35 to 38 (Cancelled).